Skip to content
Ep. 380 - AZ-BMS rumors, Replimune, psychedelics episode artwork

Aug 4, 2026 32 min

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

from BioCentury This Week Hosted by BioCentury

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal make sense? On the latest BioCentury This Week podcast, BioCentury’s analysts explain why they aren’t buying it. The team also discusses what lessons can be learned from the regulatory roller-coaster ride of Replimune’s RP1 vusolimogene oderparepvec and psychedelic therapies’ inflection point in treating depression. View full story: https://www.biocentury.com/article/660376 #BiotechMA #FDA #Psychedelics #Depression #OncolyticVirus 00:00 - Introduction 00:51 - AZ-BMS Rumors 08:07 - Replimune 20:46 - Psychedelics To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected]. Reach us by sending a text

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

0:00 32:25

Chapters

  1. 0:00 Introduction
  2. 0:51 AZ-BMS Rumors
  3. 8:07 Replimune
  4. 20:46 Psychedelics

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of BioCentury This Week?

This episode is 32 minutes long.

When was this BioCentury This Week episode published?

This episode was published on August 4, 2026.

Can I download this BioCentury This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.